VivoSeq
Oncology

NSCLC (advanced Non-Small Cell Lung Cancer)

5

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

NSCLC (Advanced Non-small Cell Lung Cancer) is an early-stage landscape with 5 programs across 5 companies. The most active players are Summit Therapeutics, Merck & Co., Bristol-Myers Squibb. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

15/100

Mech. Concentration

33/100

Completion Rate

0/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Summit Therapeutics

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3E

Eagle Vision Pharmaceutical Corp.

1 program

Phase 3N

Natera, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

5programs
Small molecule240%
Monoclonal antibody240%
Protein / enzyme120%

Modality classified for 71% of 7 pipeline programs.

Analysis

Trial Status

3

clinical trials

Not yet recruiting1 · 33%
Active, not recruiting1 · 33%
Withdrawn1 · 33%

Clinical Trials

Trial Activity

A Multicenter, Open-label, Randomized (1:1) Trial Designed to Evaluate Whether MRD-guided Intermittent ICI Therapy Provides Comparable Survival to SOC Continuous ICI Therapy in Subjects With Histologically Confirmed Advanced / Metastatic NSCLC, Melanoma, MSI-High/dMMR CRC, RCC and Other Solid Tumors.
Not yet recruiting·NNatera, Inc.·Preclinical·NCT07689812·920 enrolled
A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment
Active, not recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT07669051·36 enrolled
Phase 3, Randomized, Open-Label Study of Nogapendekin Alfa Inbakicept in Combination With Standard of Care Versus Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Withdrawn·IImmunityBio, Inc.·Phase 3·NCT07524257

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)